Last Updated on December 8, 2021 by The Health Master
The drug is approved for use in combination with standard Daunorubicin & Cytarabine induction and high-dose Cytarabine consolidation chemotherapy
And for patients in complete response followed by Midostaurin single-agent maintenance therapy for adults with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive.
The drug will have a strength of 25 mg, in the form of capsules.
For informative videos by The Health Master, click on the below YouTube icon: